Ocugen on Friday said that the US Food and Drug Administration (FDA) has declined to issue an emergency use authorisation (EUA) for Covaxin — the Covid-19 vaccine developed by its Indian partner Bharat Biotech — for use in individuals aged 2 to 18 years.

“The US FDA, at this time, has declined to issue an EUA for Covaxin for active immunisation to prevent Covid-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age,” the company said in a statement on Friday.

Also read
File picture: A health worker administers a dose of Covid-19 vaccine to a beneficiary, at a vaccination centre in Gurugram last month.

The Daily Dose, March 4, 2022

India has administered more than 178 crore total doses of the Covid-19 vaccine so far 

Covid-19 vaccination: India administered over 24 lakh doses on March 3

VK Paul, Member, Health NITI Aayog

Unvaccinated account for 92 per cent Covid deaths in India in 2022: Health Ministry

It’s widely alleged that deaths from Covid are severely under-reported worldwide

On estimating Covid’s death toll

Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of Covaxin, it added in the statement.

Ocugen is a clinical stage biopharmaceutical company which is co-developing Bharat Biotech’s Covaxin vaccine candidate for Covid-19 in the US and Canadian markets.

Related Topics
comment COMMENT NOW